Ayman Saleh

Ayman Saleh


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
Syed RizviSyed Rizvi
Syed Rizvi
ASAyman Saleh
Ayman Saleh
The development of nanoparticle-based drug formulations has yielded the opportunities to address and treat challenging diseases. Nanoparticles vary in size but are generally ranging from 100 to 500 nm. Through the manipulation of size, surface characteristics and material used, the nanoparticles can be developed into smart systems, encasing therapeutic and imaging agents as well as bearing stealth property. Further, these systems can deliver drug to specific tissues and provide controlled release therapy. This targeted and sustained drug delivery decreases the drug related toxicity and increase patient's compliance with less frequent dosing. Nanotechnology has proven beneficial in the treatment of cancer, AIDS and many other disease, also providing advancement in diagnostic testing.

1 March 2001 in Nature
Verified
Journal Article
Closed access
PDF file
SSSrinivasa M. Srinivasula
Srinivasa M. Srinivasula
RHRamesh Hegde
Ramesh Hegde
ASAyman Saleh
Ayman Saleh
PDPinaki Datta
Pinaki Datta
ESEric Shiozaki
Eric Shiozaki
EAEmad S. Alnemri
Emad S. Alnemri

6 July 2000 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ASAyman Saleh
Ayman Saleh
SSSrinivasa M. Srinivasula
Srinivasa M. Srinivasula
LBLevent Balkir
Levent Balkir
PRPaul D. Robbins
Paul D. Robbins
EAEmad S. Alnemri
Emad S. Alnemri

15 August 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
PPPramod Pandey
Pramod Pandey
ASAyman Saleh
Ayman Saleh
ANAtsuko Nakazawa
Atsuko Nakazawa
SKShailendra Kumar
Shailendra Kumar
SSSrinivasa M. Srinivasula
Srinivasa M. Srinivasula
SKSurender Kharbanda
Surender Kharbanda
The release of cytochrome c from mitochondria results in the formation of an Apaf‐1–caspase‐9 apoptosome and induces the apoptotic protease cascade by activation of procaspase‐3. The present studies demonstrate that heat shock protein 90 (Hsp90) forms a cytosolic complex with Apaf‐1 and thereby inhibits the formation of the active complex. Immunodepletion of Hsp90 depletes Apaf‐1 and thereby inhibits cytochrome c‐mediated activation of caspase‐9. Addition of purified Apaf‐1 to Hsp90‐depleted cytosolic extracts restores cytochrome c‐mediated activation of procaspase‐9. We also show that Hsp90 inhibits cytochrome c‐mediated oligomerization of Apaf‐1 and thereby activation of procaspase‐9. Furthermore, treatment of cells with diverse DNA‐damaging agents dissociates the Hsp90–Apaf‐1 complex and relieves the inhibition of procaspase‐9 activation. These findings provide the first evidence for a negative cytosolic regulator of cytochrome c‐dependent apoptosis and for involvement of a chaperone in the caspase cascade.

1 June 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ASAyman Saleh
Ayman Saleh
SSSrinivasa M. Srinivasula
Srinivasa M. Srinivasula
SASamir Acharya
Samir Acharya
RFRichard Fishel
Richard Fishel
EAEmad S. Alnemri
Emad S. Alnemri
To elucidate the mechanism of activation of procaspase-9 by Apaf-1, we produced recombinant full-length Apaf-1 and purified it to complete homogeneity. Here we show using gel filtration that full-length Apaf-1 exists as a monomer that can be transformed to an oligomeric complex made of at least eight subunits after binding to cytochrome c and dATP. Apaf-1 binds to cytochromec in the absence of dATP but does not form the oligomeric complex. However, when dATP is added to the cytochromec-bound Apaf-1 complex, complete oligomerization occurs, suggesting that oligomerization is driven by hydrolysis of dATP. This was supported by the observation that ATP, but not the nonhydrolyzable adenosine 5′-O-(thiotriphosphate), can induce oligomerization of the Apaf-1-cytochrome c complex. Like the spontaneously oligomerizing Apaf-530, which lacks its WD-40 domain, the oligomeric full-length Apaf-1-cytochrome c complex can bind and process procaspase-9 in the absence of additional dATP or cytochrome c. However, unlike the truncated Apaf-530 complex, the full-length Apaf-1 complex can release the mature caspase-9 after processing. Once released, mature caspase-9 can process procaspase-3, setting into motion the caspase cascade. These observations indicate that cytochrome c and dATP are required for oligomerization of Apaf-1 and suggest that the WD-40 domain plays an important role in oligomerization of full-length Apaf-1 and the release of mature caspase-9 from the Apaf-1 oligomeric complex.

1 October 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ASAyman Saleh
Ayman Saleh
DSDavid Schieltz
David Schieltz
NTNicholas Ting
Nicholas Ting
SMSteven B. McMahon
Steven B. McMahon
DLDavid W. Litchfield
David W. Litchfield
CBChristopher J. Brandl
Christopher J. Brandl
The yeast Ada and TBP class of Spt proteins interact in multiple complexes that are required for transcriptional regulation. We have identified Tra1p as a component of these complexes through tandem mass spectrometry analysis of proteins that associate with Ngg1p/Ada3p. TRA1 is an essential gene and encodes a 3744-amino acid protein that is a member of a group of proteins including the catalytic subunit of DNA-dependent protein kinase, ATM and TRRAP, with carboxyl-terminal regions related to phosphatidylinositol 3-kinases. The interaction between Tra1p and Ada/Spt components was verified by the reciprocal coimmunoprecipitation of Ada2p and Tra1p from whole cell extracts in one or more complexes containing Spt7p. Tra1p cofractionated with Ngg1p and Spt7p through consecutive chromatography on Mono Q, DNA-cellulose, and Superose 6 columns. Binding of Tra1p to DNA-cellulose required Ada components. The association of Tra1p with two Ada·Spt complexes was suggested by its cofractionation with Ngg1p and Spt7p in two peaks on the Mono Q column. In the absence of Ada2p, the elution profile of Tra1p shifted to a distinct peak. Despite the similarity of Tra1p to a group of putative protein kinases, we have not detected protein kinase activity within immunoprecipitates of Tra1p or the Ada·Spt complexes.